PDF icon Download PDF
Pneumologie 2008; 62(12): 718-729
DOI: 10.1055/s-2008-1038270
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle und neue Medikamente in der Tabakentwöhnung

Current and Future Medical Drugs for Smoking CessationB.  Kusma1, 2 , S.  Mache1 , F.  Deissenrieder1 , D.  Quarcoo1 , T.  Welte2 , D.  Groneberg1
  • 1Institut für Arbeitsmedizin, Charité Universitätsmedizin Berlin (Direktor: Univ.-Prof. Dr. D. Groneberg)
  • 2Abteilung Pneumologie, Zentrum Innere Medizin, Medizinische Hochschule Hannover (Direktor: Univ.-Prof. Dr. T. Welte)
Further Information

Publication History

Publication Date:
02 December 2008 (online)

Also available ateRef
   Permissions and Reprints
Preview

Lerninhalte

Grundlagenwissen zur Epidemiologie und Auswirkungen von Tabakkonsum Grundlagenwissen zur neurobiologischen Wirkung des Rauchens Definition von Tabaksucht Differenzierte Beschreibung der Therapieformen der Tabakentwöhnung, Vergleich von pharmakologischen und verhaltenstherapeutischen Ansätzen

Literatur

  • 1 World Health Organization .The facts about smoking and health. 2006
    Search in Google Scholar
  • 2 Becker N, Wahrendorf J H. Krebsatlas der Bundesrepublik Deutschland 1981 – 1990. Heidelberg: Springer 1998
    Search in Google Scholar
  • 3 Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (GKID) .Krebs in Deutschland. Häufigkeiten und Trends. Saarbrücken: Krebsregister 2006
    Search in Google Scholar
  • 4 Deutsches Krebsforschungszentrum (DKFZ) .Passivrauchende Kinder in Deutschland – Frühe Schädigungen für ein ganzes Leben. Heidelberg 2003
    Search in Google Scholar
  • 5 US Department of Health and Human Services .The health benefits of smoking cessation: A report of the Surgeon General. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, Center for Chronic Disease Prevention and Health Promotion, Public Health Service, Office on Smoking and Health 1990
    Search in Google Scholar
  • 6 Balfour D J, Fagerstrom K O. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders.  Pharmacol Ther. 1996;  72 51-81
    Search in Google Scholar
  • 7 Balfour D J, Benwell M E, Birrell C E. et al . Sensitization of the mesoaccumbens dopamine response to nicotine.  Pharmacol Biochem Behav. 1998;  59 1021-1030
    Search in Google Scholar
  • 8 Pomerleau O F. Nicotine and the central nervous system: biobehavioral effects of cigarette smoking.  Am J Med. 1992;  93 2S-7S
    Search in Google Scholar
  • 9 Epping-Jordan M P, Watkins S S, Koob G F. et al . Dramatic decreases in brain reward function during nicotine withdrawal.  Nature. 1998;  393 76-79
    Search in Google Scholar
  • 10 Picciotto M R, Zoli M, Rimondini R. et al . Acetylcholine receptors containing the beta 2 subunit are involved in the reinforcing properties of nicotine.  Nature. 1998;  391 173-177
    Search in Google Scholar
  • 11 Furtado R. Implicações anestésicas do tabagismo.  Rev Bras Anestesiol. 2002;  52 354-367
    Search in Google Scholar
  • 12 Batra A. Tabakabhängigkeit. Biologische und psychosoziale Entstehungsbedingungen und Therapiemöglichkeiten. Darmstadt: Steinkopf 2000
    Search in Google Scholar
  • 13 Marques A CPR. et al . Consenso sobre o tratamento da dependência de nicotina.  Rev Bras Psiquiatr. 2001;  23 200-214
    Search in Google Scholar
  • 14 US Department of Health and Human Services .The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General. Rockville, Maryland 1988
    Search in Google Scholar
  • 15 Dilling H, Monbour W, Schmidt M H. Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F). Göttingen: Huber 1991
    Search in Google Scholar
  • 16 Saß H, Wittchen H U, Zaudig M. Diagnostisches und Statistisches Manual Psychischer Störungen DSM IV. Göttingen, Bern, Toronto, Seattle: Hogrefe 1996
    Search in Google Scholar
  • 17 Batra A, Fagerström K O. Neue Aspekte der Nikotinabhängigkeit und Raucherentwöhnung.  Sucht. 1997;  43 277-282
    Search in Google Scholar
  • 18 Breslau N, Johnson E O, Hiripi E. et al . Nicotine dependence in the United States: prevalence, trends, and smoking persistence.  Arch Gen Psychiatry. 2001;  58 810-816
    Search in Google Scholar
  • 19 World Health Organization .Tobacco or health: a global status report. Geneva: World Health Organization 1997
    Search in Google Scholar
  • 20 Fagerstrom K O, Schneider N G. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire.  J Behav Med. 1989;  12 159-182
    Search in Google Scholar
  • 21 Lagrue G, Lafnoune N, Cormier S. et al . Urinary cotinine-creatinine ratio as a marker of nicotine intake: a guide for the nicotine replacement therapy during smoking cessation. Congrès annuel ERS, Florence 1993.  Eur Respir J. 1993;  6
    Search in Google Scholar
  • 22 Fiore M C, Bailey W C, Cohen S J. Treating tobacco use and dependence. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service 2000
    Search in Google Scholar
  • 23 Haustein K O. Pharmacotherapy of nicotine dependence.  Int J Clin Pharmacol Ther. 2000;  38 273-290
    Search in Google Scholar
  • 24 Henningfield J E. Nicotine medications for smoking cessation.  N Engl J Med. 1995;  333 1196-1203
    Search in Google Scholar
  • 25 Mühling S, Nowak D. 9 Thesen zur Raucherentwöhnung.  Suchtmed. 2004;  6
    Search in Google Scholar
  • 26 Nowak D, Hoch E. Raucherentwöhnung – Pharmakologie, Effizienz und Hemmnisse.  Bay Int. 2005;  25 118-126
    Search in Google Scholar
  • 27 Schön S, Nowak D. Medikamentöse Verfahren zur Raucherentwöhnung.  Suchtmed. 2002;  4 189-199
    Search in Google Scholar
  • 28 Silagy C, Lancaster T, Stead L. et al . Nicotine replacement therapy for smoking cessation.  Cochrane Database Syst Rev. 2004;  CD000146
    Search in Google Scholar
  • 29 Henningfield J E, Fant R V, Buchhalter A R. et al . Pharmacotherapy for nicotine dependence.  CA Cancer J Clin. 2005;  55 281-299; quiz 322 – 283, 325
    Search in Google Scholar
  • 30 Mitrouska I, Bouloukaki I, Siafakas N M. Pharmacological approaches to smoking cessation.  Pulm Pharmacol Ther. 2007;  20 220-232
    Search in Google Scholar
  • 31 Wu P, Wilson K, Dimoulas P. et al . Effectiveness of smoking cessation therapies: a systematic review and meta-analysis.  BMC Public Health. 2006;  6 300
    Search in Google Scholar
  • 32 Fiore M C. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline.  Respir Care. 2000;  45 1196-1199
    Search in Google Scholar
  • 33 Hjalmarson A, Franzon M, Westin A. et al . Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study.  Arch Intern Med. 1994;  154 2567-2572
    Search in Google Scholar
  • 34 Sutherland G, Stapleton J A, Russell M A. et al . Randomised controlled trial of nasal nicotine spray in smoking cessation.  Lancet. 1992;  340 324-329
    Search in Google Scholar
  • 35 Sutherland G, Russell M A, Stapleton J. et al . Nasal nicotine spray: a rapid nicotine delivery system.  Psychopharmacology (Berl). 1992;  108 512-518
    Search in Google Scholar
  • 36 Choi J H, Dresler C M, Norton M R. et al . Pharmacokinetics of a nicotine polacrilex lozenge.  Nicotine Tob Res. 2003;  5 635-644
    Search in Google Scholar
  • 37 Shiffman S, Dresler C M, Hajek P. et al . Efficacy of a nicotine lozenge for smoking cessation.  Arch Intern Med. 2002;  162 1267-1276
    Search in Google Scholar
  • 38 Blondal T, Gudmundsson L J, Olafsdottir I. et al . Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up.  Bmj. 1999;  318 285-288
    Search in Google Scholar
  • 39 Bohadana A, Nilsson F, Rasmussen T. et al . Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial.  Arch Intern Med. 2000;  160 3128-3134
    Search in Google Scholar
  • 40 Kornitzer M, Boutsen M, Dramaix M. et al . Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial.  Prev Med. 1995;  24 41-47
    Search in Google Scholar
  • 41 Benowitz N L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.  Clin Pharmacol Ther. 2008;  83 531-541
    Search in Google Scholar
  • 42 Hays J T, Ebbert J O. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits.  CNS Drugs. 2003;  17 71-83
    Search in Google Scholar
  • 43 Slemmer J E, Martin B R, Damaj M I. Bupropion is a nicotinic antagonist.  J Pharmacol Exp Ther. 2000;  295 321-327
    Search in Google Scholar
  • 44 Hurt R D, Sachs D P, Glover E D. et al . A comparison of sustained-release bupropion and placebo for smoking cessation.  N Engl J Med. 1997;  337 1195-1202
    Search in Google Scholar
  • 45 Lee A M, Jepson C, Hoffmann E. et al . CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.  Biol Psychiatry. 2007;  62 635-641
    Search in Google Scholar
  • 46 Jorenby D E, Leischow S J, Nides M A. et al . A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.  N Engl J Med. 1999;  340 685-691
    Search in Google Scholar
  • 47 Hughes J R, Stead L F, Lancaster T. Antidepressants for smoking cessation.  Cochrane Database Syst Rev. 2007;  CD000031
    Search in Google Scholar
  • 48 Roddy E. Bupropion and other non-nicotine pharmacotherapies.  Bmj. 2004;  328 509-511
    Search in Google Scholar
  • 49 George T P, O'Malley S S. Current pharmacological treatments for nicotine dependence.  Trends Pharmacol Sci. 2004;  25 42-48
    Search in Google Scholar
  • 50 Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation.  Drugs. 2002;  62 Suppl 2 5-35
    Search in Google Scholar
  • 51 Aubin H J. Tolerability and safety of sustained-release bupropion in the management of smoking cessation.  Drugs. 2002;  62 Suppl 2 45-52
    Search in Google Scholar
  • 52 Settle Jr E C. Bupropion sustained release: side effect profile.  J Clin Psychiatry. 1998;  59 Suppl 4 32-36
    Search in Google Scholar
  • 53 da Costa C L, Younes R N, Lourenco M T. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo.  Chest. 2002;  122 403-408
    Search in Google Scholar
  • 54 Hall S M, Reus V I, Munoz R F. et al . Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking.  Arch Gen Psychiatry. 1998;  55 683-690
    Search in Google Scholar
  • 55 Ferry L H. Non-nicotine pharmacotherapy for smoking cessation.  Prim Care. 1999;  26 653-669
    Search in Google Scholar
  • 56 Abbot N C, Stead L F, White A R. et al . Hypnotherapy for smoking cessation.  Cochrane Database Syst Rev. 2000;  CD001008
    Search in Google Scholar
  • 57 Prochazka A V, Kick S, Steinbrunn C. et al . A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation.  Arch Intern Med. 2004;  164 2229-2233
    Search in Google Scholar
  • 58 Gourlay S G, Stead L F, Benowitz N L. Clonidine for smoking cessation.  Cochrane Database Syst Rev. 2004;  CD000058
    Search in Google Scholar
  • 59 Jorenby D E, Hays J T, Rigotti N A. et al . Efficacy of varenicline, an alpha-4-beta-2-nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.  Jama. 2006;  296 56-63
    Search in Google Scholar
  • 60 Cohen C, Perrault G, Voltz C. et al . SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.  Behav Pharmacol. 2002;  13 451-463
    Search in Google Scholar
  • 61 Anthenelli R, Despres J. Effects of rimonabant in the reduction of major car-diovascular risk factors. Results from the STRATUS-US trial (smoking cessation in smokers motivated to quit). Presented at Am. College Cardiol. 53rd Annu. Sci. Session. New Orleans, LA: Rapid News Summaries 2004
    Search in Google Scholar
  • 62 Anthenelli R. Rimonabantin smoking abstinence: the STRATUS-programm. in Proc. 11 Annu. Meet. Soc. Res. Nicotine Tobacco. Prague, Czech 2005
    Search in Google Scholar
  • 63 EMEA .Questions and answers on the safety of Acomplia (Rimonabant).  http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/H-666-qa.pdf. London: European Medicines Agency 2007
    Search in Google Scholar
  • 64 Cerny T. Anti-nicotine vaccination: where are we?.  Recent Results Cancer Res. 2005;  166 167-175
    Search in Google Scholar
  • 65 Hieda Y, Keyler D E, Ennifar S. et al . Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain.  Int J Immunopharmacol. 2000;  22 809-819
    Search in Google Scholar
  • 66 Pentel P R, Malin D H, Ennifar S. et al . A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats.  Pharmacol Biochem Behav. 2000;  65 191-198
    Search in Google Scholar
  • 67 Le Houezec J. Why a nicotine vaccine?.  Clin Pharmacol Ther. 2005;  78 453-455
    Search in Google Scholar
  • 68 LeSage M G, Keyler D E, Pentel P R. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies.  Aaps J. 2006;  8 E65-75
    Search in Google Scholar
  • 69 Lindblom N, de Villiers S H, Kalayanov G. et al . Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats.  Respiration. 2002;  69 254-260
    Search in Google Scholar
  • 70 Cytos Biotechnology .Impfstoff zur Behandlung der Nikotinsucht fördert anhaltende Abstinenz während 12 Monaten bei Probanden mit hohen Antikörperwerten.  http://www.cytos.com/doc/Cytos_Press_D_051 117.pdf. Schlieren: Cytos Biotechnology AG 2005
    Search in Google Scholar
  • 71 Hatsukami D K, Rennard S, Jorenby D. et al . Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.  Clin Pharmacol Ther. 2005;  78 456-467
    Search in Google Scholar
  • 72 Maurer P, Jennings G T, Willers J. et al . A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity.  Eur J Immunol. 2005;  35 2031-2040
    Search in Google Scholar
  • 73 White A R, Rampes H, Campbell J L. Acupuncture and related interventions for smoking cessation.  Cochrane Database Syst Rev. 2006;  CD000009
    Search in Google Scholar
  • 74 Balbani A, Montovani J. Methods for smoking cessation and treatment of nicotine dependence.  Rev Bras Otorrinolaringol. 2005;  71 820-827
    Search in Google Scholar
  • 75 Villano L M, White A R. Alternative therapies for tobacco dependence.  Med Clin North Am. 2004;  88 1607-1621
    Search in Google Scholar
  • 76 Stead L F, Lancaster T. Group behaviour therapy programmes for smoking cessation.  Cochrane Database Syst Rev. 2002;  CD001007
    Search in Google Scholar
  • 77 West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority.  Thorax. 2000;  55 987-999
    Search in Google Scholar
  • 78 Deutsche Hauptstelle gegen die Suchtgefahren e. V. (DHS) .Frau SUCHT Gesundheit. Die Luft anhalten oder: Warum rauchen Frauen?.  http://www.dhs.de/makeit/cms/cms_upload/dhs/die_luft_anhalten_low.pdf Hamm 2000
    Search in Google Scholar

Dipl. Psych. Bianca Kusma

Institut für Arbeitsmedizin

Thielallee 69 – 73

14159 Berlin

Email: bianca.kusma@charite.de